Galapagos NV (GLPG) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals several negative factors: significant financial impacts from the cell therapy wind-down, strategic reorganization costs, and currency exchange risks. Although there is a strong cash position and improved operating profit, the dependency on Gilead and lack of clear guidance on cost management raise concerns. The Q&A section highlights management's avoidance of specifics on cost reduction and breakeven timelines, adding uncertainty. These factors, combined with the strategic reorganization costs and potential financial challenges, suggest a negative stock price movement in the next two weeks.
Key Financial Performance
Year-end cash position Approximately EUR 3 billion, a strong position to pursue transformative business development opportunities with significant strategic flexibility.
Total operating profit from continuing operations EUR 295.1 million in 2025 compared to an operating loss of EUR 188.3 million in 2024. This improvement was primarily due to the release in revenue of the remaining deferred income balance of EUR 1,069 million associated with the exclusive access rights granted to Gilead under the OLCA.
Operating expenses Negatively impacted for a total of EUR 399.8 million by the decision to wind down the cell therapy activities, including an impact of EUR 275 million (impairment of EUR 228.1 million, severance costs of EUR 33.3 million, early termination of collaborations of EUR 16.3 million, deal cost of EUR 10.1 million, and other costs).
Financial investments and cash and cash equivalents EUR 2,998 million on December 31, 2025, compared to EUR 3,317.8 million on December 31, 2024. The decrease is attributed to strategic reorganization and other operational costs.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
GLPG3667 (TYK2): Achieved primary endpoint in Phase II trials for dermatomyositis and systemic lupus erythematosus (SLE), showing statistically significant clinical benefits. Strategic options, including partnerships, are being evaluated to accelerate development.
Collaboration with Gilead: Continues to be a strategic advantage, leveraging Gilead's global development and commercialization expertise alongside Galapagos' capital base and deal-making skills.
Financial Position: Ended 2025 with approximately EUR 3 billion in cash, providing strategic flexibility for business development.
Cell Therapy Wind Down: Decision to wind down cell therapy activities resulted in EUR 399.8 million in operating expenses, with the process expected to be substantially completed by Q3 2026.
2025 Financial Results: Achieved EUR 295.1 million operating profit, reversing a EUR 188.3 million loss in 2024, primarily due to revenue recognition from deferred income.
Strategic Shift: Transitioned focus from cell therapy to clinically derisked opportunities in areas with competitive advantages, aiming for meaningful patient impact and sustainable shareholder returns.
Leadership and Board Changes: Assembled a new management team with extensive business development expertise and added five new directors to the Board to support the strategic shift.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Cell Therapy Wind Down: The decision to wind down cell therapy activities has led to significant financial impacts, including an impairment of EUR 228.1 million, severance costs of EUR 33.3 million, and other associated costs. This restructuring process is expected to result in an operating cash outflow of up to EUR 50 million in Q1 2026 and one-time restructuring cash impacts of EUR 125 million to EUR 175 million in 2026.
Strategic Reorganization Costs: The strategic reorganization related to the small molecules business announced in 2025 incurred costs of EUR 124.8 million, reflecting the financial burden of transitioning to a new strategic direction.
Currency Exchange Risks: The company holds a significant portion of its cash in U.S. dollars (72%), exposing it to potential currency exchange risks, especially given the ongoing conversion of euros to U.S. dollars.
TYK2 Program Costs: The ongoing TYK2 program, including Phase II clinical trials and preparation for Phase III development, is expected to cost up to EUR 40 million in 2026, representing a financial challenge in advancing this legacy R&D asset.
Dependency on Gilead Collaboration: The collaboration with Gilead, while a strategic advantage, creates dependency risks as future business development transactions may need to be renegotiated under different terms, potentially impacting financial outcomes.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
2026 Guidance: The company expects the wind down of cell therapy activities to be substantially completed by the end of Q3 2026. This includes an operating cash outflow of up to EUR 50 million in Q1 2026 and one-time restructuring cash impacts of EUR 125 million to EUR 175 million in 2026, reflecting a EUR 25 million reduction from prior guidance. Costs related to the ongoing TYK2 program, including Phase II clinical trials and advancing towards Phase III development, are expected to be up to EUR 40 million in 2026. The company anticipates being cash flow neutral to positive by the end of 2026, with cash, cash equivalents, and financial investments projected to be approximately EUR 2.775 billion to EUR 2.850 billion at year-end 2026, excluding business development activities or currency fluctuations.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the company's current strategy for business development and any deadlines related to the Gilead agreement?
A:The company is focusing on derisked late-stage clinical assets, primarily in the i&i and oncology space, and is confident in the opportunities available. There is no set deadline for a specific deal, as the company prioritizes doing the right deal over meeting a timeline. The OLCA agreement with Gilead expires in about 3 years, which serves as an ultimate deadline.
Q:What is the company's stance on developing GLPG3667 internally versus out-licensing?
A:The company maintains a high bar for developing GLPG3667 internally or externally. They are still analyzing data and exploring partnerships, as they lack the infrastructure to take the asset into Phase III. Partnering could allow for faster, more capital-efficient development and greater value creation.
Q:What is the company's current view on capital allocation for acquisitions and operating expenses, and how does the Gilead partnership influence this?
A:The company has EUR 3 billion in capital, which must cover both acquisitions and development expenses. The partnership with Gilead is constructive, with Gilead open to contributing to deal terms and development costs, allowing the company to go beyond its EUR 3 billion capital pool.
Q:What are the expectations for lower cell therapy wind-down costs?
A:The company has reduced the range of one-time restructuring costs from EUR 150-200 million to EUR 125-175 million. They will provide updates on cost progression in future calls.
Q:Why did the company transition more euros to dollars, and what is the expected impact on financial income?
A:The transition was based on expected business development activity and a shift in the cost base towards the U.S. The company expects higher earnings rates on U.S. dollars (around 4%) compared to euros (around 2%), despite exchange rate fluctuations.
Q:When does the company expect to break even in terms of operating income?
A:The company expects to be cash flow neutral to positive by year-end, though the timing of costs related to the wind-down may vary by quarter.
Q:Review of Unclear Management Responses
A:Management avoided providing future guidance on lower cell therapy wind-down costs and did not specify a timeline for breaking even in operating income, citing variability in cost timing.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Chief Officer
Cox
EUR dollar
Head Investor
II
OLCA
SLE
activity EUR
advantage
allocation experience
capital allocation
cash EUR
cash dollar
cash equivalent
cash flow
contract liability
cost
deal
development opportunity
dialogue
dollar euro
equivalent investment
flexibility
intention
level
obligation
opportunity focus
plan
player
press release
result update
shareholder
therapy activity
today Galapagos
GLPG Transcript
Galapagos NV (GLPG) Q4 2025 Earnings Call Transcript
Unknown2-24
The earnings call reveals several negative factors: significant financial impacts from the cell therapy wind-down, strategic reorganization costs, and currency exchange risks. Although there is a strong cash position and improved operating profit, the dependency on Gilead and lack of clear guidance on cost management raise concerns. The Q&A section highlights management's avoidance of specifics on cost reduction and breakeven timelines, adding uncertainty. These factors, combined with the strategic reorganization costs and potential financial challenges, suggest a negative stock price movement in the next two weeks.
Galapagos NV (GLPG) Q3 2025 Earnings Call Transcript
Unknown11-6
The earnings call summary presents mixed signals. Financial performance shows a decrease in cash and interest income, but strategic currency shifts and stable income from royalties are positives. The Q&A highlights a focus on strategic partnerships, particularly with Gilead, but lacks clarity on deal specifics and internal pipeline strategies. The absence of strong guidance or new partnership announcements tempers expectations. Overall, the sentiment is balanced, suggesting a neutral stock price movement.
Galapagos NV (GLPG) Q3 2024 Earnings Call Transcript
Positive10-31
The earnings call presents a stable financial position with a significant cash reserve and a net profit, despite a high cash burn rate. The strategic partnerships and regulatory progress in CAR-T therapies, along with a focus on oncology and immunology, are positive indicators. The Q&A reveals confidence in addressing potential therapy side effects and ongoing business development. However, some concerns remain about competitive pressures and logistical challenges. Overall, the sentiment is positive, with potential for stock price growth driven by strategic advancements and strong cash management.
Galapagos NV (GLPG) Q2 2024 Earnings Call Transcript
Unknown8-2
The earnings call summary reveals several concerns: increased cash burn guidance, safety issues in trials, and competitive pressures. The Q&A section highlights potential regulatory delays and safety concerns, particularly with Parkinsonism in CAR-T therapies, which could hinder growth. Although the cash position is strong, the financial risks and operational challenges outweigh positives. The management's vague responses in the Q&A add to uncertainties. Given these factors, the stock price is likely to react negatively over the next two weeks.
GLPG Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
